tarlatamab在铂类化疗后小细胞肺癌的延长随访:DeLLphi-304 III期随机研究
DeLLphi-304 III期开放标签研究在铂类化疗后进展的SCLC患者中1:1随机接受tarlatamab或化疗,延长随访至中位约23个月时,tarlatamab组中位OS为13.6个月对8.4个月,中位PFS为4.2个月对3.2个月,长期耐受性良好,支持其作为该人群标准治疗。
要点
- 延长随访显示tarlatamab较化疗持续改善OS和PFS,24个月OS率为30.3%对14.9%。
- tarlatamab组ORR为35.4%,持续缓解和≥52周疾病控制比例均高于化疗。
- TRAE导致停药比例3.2%对6.6%,≥12个月无新发严重TRAE,CRS和ICANS多为低级别且早期发生。
核心结论
- 延长随访下tarlatamab在铂类化疗后SCLC患者中较化疗持续显示持久临床获益和良好长期耐受性,支持其作为该场景标准治疗。
研究设计与样本
- III期开放标签随机对照研究,SCLC患者铂类化疗后进展按1:1随机接受tarlatamab或化疗(拓扑替康、芦比替定或氨柔比星),主要终点为OS。
主要发现
- 截至2026年2月18日,tarlatamab组与化疗组中位OS分别为13.6个月和8.4个月,中位随访分别为23.3个月和22.8个月。
- tarlatamab组与化疗组中位PFS分别为4.2个月和3.2个月,中位随访分别为22.2个月和21.9个月。
- 12个月和24个月OS率分别为55.9%和30.3%对39%和14.9%,对应PFS率分别为20.6%和14.2%对5.9%和2.3%。
- tarlatamab组ORR为35.4%(含6例确认完全缓解),化疗组为20.4%;截至数据截止时持续缓解者分别为31.1%(28/90)和3.8%(2/52)。
- 持续≥52周疾病控制率分别为24.4%和4.3%;TRAE导致停药分别为3.2%和6.6%,≥3级事件随时间减少,≥12个月无新发严重TRAE。
临床怎么用
- 对于一线铂类化疗后进展的SCLC患者,tarlatamab可作为优先推荐的治疗选择。
- 治疗早期需关注细胞因子释放综合征和免疫效应细胞相关神经毒性综合征,多为低级别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS; P < 0.001), progression-free survival (PFS; P = 0.002), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy. We report efficacy and safety outcomes after extended follow-up in patients with small-cell lung cancer (SCLC). PATIENTS AND METHODS: In this phase III, open-label trial, patients with SCLC whose disease had progressed on or after platinum-based chemotherapy were randomly assigned (1 : 1) to receive either tarlatamab or chemotherapy (topotecan, lurbinectedin, or amrubicin) until disease progression, unacceptable toxicity, or death. The primary endpoint was OS. Secondary endpoints included investigator-assessed PFS, objective response, disease control, duration of response per RECIST v1.1, PROs, and safety. RESULTS: As of data cut-off (18 February 2026), median OS was 13.6 and 8.4 months with tarlatamab and chemotherapy, respectively (median follow-up, 23.3 and 22.8 months). Median PFS was 4.2 and 3.2 months, respectively (median follow-up, 22.2 and 21.9 months). Kaplan-Meier estimated OS rates at 12 and 24 months were 55.9% and 30.3% with tarlatamab versus 39% and 14.9% with chemotherapy; corresponding PFS rates at 12 and 24 months were 20.6% and 14.2% versus 5.9% and 2.3%. Objective response rate was 35.4% with tarlatamab, including six confirmed complete responses versus 20.4% with chemotherapy; at data cut-off, ongoing responses were observed in 31.1% (28 of 90) versus 3.8% (2 of 52) of responders, respectively. Sustained disease control for ≥52 weeks was observed in 24.4% versus 4.3%. Treatment-related adverse events (TRAEs) led to treatment discontinuation in 3.2% versus 6.6%; grade ≥3 events decreased over time, with no serious TRAEs with onset ≥12 months. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred early in treatment and were predominantly low grade. CONCLUSIONS: With extended follow-up, tarlatamab continues to demonstrate sustained and durable clinical benefit and a favorable long-term tolerability profile versus chemotherapy, in patients with SCLC after first-line platinum-based chemotherapy, supporting its use as the standard of care in this setting.
引用
- Rudin CM, Ahn MJ, Schuler M, et al. Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study. Ann Oncol. 2026. PMID: 42933636. doi:10.1016/j.annonc.2026.10.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。